These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 22157367

  • 1. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.
    Chen YM, Tsai CM, Fan WC, Shih JF, Liu SH, Wu CH, Chou TY, Lee YC, Perng RP, Whang-Peng J.
    J Thorac Oncol; 2012 Feb; 7(2):412-8. PubMed ID: 22157367
    [Abstract] [Full Text] [Related]

  • 2. Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
    Heigener DF, Deppermann KM, Pawel JV, Fischer JR, Kortsik C, Bohnet S, Eiff MV, Koester W, Thomas M, Schnabel PA, Reck M.
    Lung Cancer; 2014 Apr; 84(1):62-6. PubMed ID: 24560332
    [Abstract] [Full Text] [Related]

  • 3. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N.
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [Abstract] [Full Text] [Related]

  • 4. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [Abstract] [Full Text] [Related]

  • 5. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE.
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
    Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K.
    J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR, Burris HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD.
    J Clin Oncol; 2011 Jun 20; 29(18):2582-9. PubMed ID: 21576636
    [Abstract] [Full Text] [Related]

  • 8. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.
    J Thorac Oncol; 2013 Jul 20; 8(7):892-8. PubMed ID: 23591159
    [Abstract] [Full Text] [Related]

  • 9. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
    Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E, Froesch P, Stahel R, Hess T, Rauch D, Schmid P, Mayer M, Crowe S, Brauchli P, Ribi K, Pless M, Swiss Group for Clinical Cancer Research (SAKK).
    Lung Cancer; 2012 Dec 20; 78(3):239-44. PubMed ID: 23009726
    [Abstract] [Full Text] [Related]

  • 10. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D.
    J Thorac Oncol; 2010 Oct 20; 5(10):1616-22. PubMed ID: 20736854
    [Abstract] [Full Text] [Related]

  • 11. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A, Takeshita J, Otsuka K, Nishino K, Uchida J, Okuyama T, Namba Y, Mori M, Fujita S, Morita S.
    Lung Cancer; 2015 Sep 20; 89(3):301-5. PubMed ID: 26141215
    [Abstract] [Full Text] [Related]

  • 12. Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
    Fan WC, Yu CJ, Tsai CM, Huang MS, Lai CL, Hsia TC, Tien YJ, Huang SF, Wu CH, Chou KT, Lee YC, Perng RP, Chen YM.
    J Thorac Oncol; 2011 Jan 20; 6(1):148-55. PubMed ID: 21107294
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    Minami S, Kijima T, Hamaguchi M, Nakatani T, Koba T, Takahashi R, Takeuchi Y, Kida H, Nagatomo I, Yamamoto S, Tachibana I, Komuta K, Kawase I.
    Lung Cancer; 2013 Nov 20; 82(2):271-5. PubMed ID: 23993733
    [Abstract] [Full Text] [Related]

  • 14. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr 20; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

  • 15. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
    Fiala O, Pesek M, Finek J, Krejci J, Ricar J, Bortlicek Z, Benesova L, Minarik M.
    Neoplasma; 2013 Apr 20; 60(1):26-32. PubMed ID: 23067213
    [Abstract] [Full Text] [Related]

  • 16. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
    Pluquet E, Cadranel J, Legendre A, Faller MB, Souquet PJ, Zalcman G, Perol M, Fraboulet G, Oliveiro G, De Fraipont F, Quoix E, Lantuejoul S, Milleron B, Moro-Sibilot D.
    J Thorac Oncol; 2010 Apr 20; 5(4):491-6. PubMed ID: 20195171
    [Abstract] [Full Text] [Related]

  • 17. Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer.
    Takatani H, Nakamura Y, Nagashima S, Soda H, Kinoshita A, Fukuda M, Fukuda M, Soejima Y, Kasai T, Nakatomi K, Iida T, Oka M, Tsukamoto K, Kohno S.
    Clin Lung Cancer; 2012 Sep 20; 13(5):347-51. PubMed ID: 22264660
    [Abstract] [Full Text] [Related]

  • 18. Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
    Kosmidis PA, Syrigos K, Kalofonos HP, Dimopoulos MA, Skarlos D, Pavlidis N, Boukovinas I, Bafaloukos D, Pectasides D, Bacoyiannis C, Fountzilas G.
    Anticancer Res; 2012 Jan 20; 32(1):175-81. PubMed ID: 22213304
    [Abstract] [Full Text] [Related]

  • 19. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M, Okayama Lung Cancer Study Group.
    J Thorac Oncol; 2010 Jan 20; 5(1):99-104. PubMed ID: 19898258
    [Abstract] [Full Text] [Related]

  • 20. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N.
    Cancer Chemother Pharmacol; 2012 May 20; 69(5):1241-6. PubMed ID: 22278730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.